Financial Performance - Net Sales reached $902 million, a 9% increase compared to Q3 2024, or 6% at constant currency[5, 9, 21] - Adjusted EBIT was $133 million with a 14.7% margin, up $16 million from Q3 2024[6, 9, 24] - Adjusted Free Cash Flow was $107 million[7, 16] Business Highlights - Light vehicle gasoline sales grew by 10%, outperforming the industry due to increased market share[9] - The company repurchased $84 million of common stock in Q3, bringing the year-to-date total to $136 million[10] - The Q4 dividend was increased by $0.02 per share to $0.08 per share[10] Outlook and Strategy - The midpoint outlook for 2025 has been raised, with Net Sales projected between $3.5 billion and $3.6 billion[7, 35] - The company is targeting to return 75% of Adjusted Free Cash Flow to shareholders over time[29] - The company expects over $100 million in sales from the industrial portfolio in 2025[41]

American Airlines Group Inc. THIRD RTER GIAL ULIS October 23, 2025 d by operating activities less net cash used in investing activities, adjusted for (1) net purchases or sales of short-term investments and (2) chan d of this presentation. The company is unable to reconcile forward-looking free cash flow to GAAP as the nature or amount of items that impact net cash 2 Third-quarter 2025 results met our financial commitments les debt. finance and operating lease liabilities and pension obligations Record thir ...

Financial Performance in Fiscal Year 2025 - The company reported net sales growth of 9%[9], with organic net sales growth of 3%[9] - Adjusted EBITDA grew by 3%[9] - Quest's FY25 organic net sales increased by 13% year-over-year[14], reflecting nearly 20% 5-Year CAGR[14] - OWYN's full fiscal year retail takeaway grew 34%[25] - Atkins' FY25 retail takeaway declined 10%[19] - Q4 2025 reported net sales grew -1.8% year-over-year to $363.5 million[32] from $351.1 million[32] in Q4 2024 - Q4 2025 Adjusted EBITDA decreased 14.5% year-over-year to $66.2 million[34] from $77.5 million[34] in Q4 2024 - Fiscal Year 2025 net sales increased 9% year-over-year to $1,450.9 million[36] from $1,306.7 million[36] in FY24 - Fiscal Year 2025 Adjusted EBITDA increased 3.4% year-over-year to $278.2 million[38] from $269.1 million[38] in FY24 Fiscal Year 2026 Outlook - The company anticipates net sales to be between -2% to +2%[10][46] - Adjusted EBITDA is projected to be between -4% to +1%[10][46]

Investor Presentation October 23, 2025 WYNDHAM HOTELS & RESORTS La Quinta Inn & Suites by Wyndham Phoenix, Arizona, USA Opened August 2025 Introduction to Wyndham Hotels & Resorts Largest hotel franchisor worldwide(a) Leading brands in the resilient select-service segment Asset-light business model generating significant free cash flow Primarily leisure-focused, "drive to" portfolio of hotels ~8.300" Hotels ~855,000~ Current Rooms ~257,000 ~70% Leisure Guest Mix Data is approximated as of September 30, 2025 ...

Vopimetostat (TNG462) Overview - Vopimetostat is an oral, once-a-day, MTAP-selective PRMT5 inhibitor with a potential best-in-class safety profile[7] - Key indications for development include pancreatic cancer (~20,000 patients/yr), lung cancer (~22,000 patients/yr), and histology agnostic cancers (~20,000 patients/yr) in the US[7] - A pivotal study in second-line (2L) pancreatic cancer is planned to initiate in 2026, with the potential to be first-to-market in 2L MTAP-del pancreatic cancer[7] Clinical Trial Data and Efficacy - Vopimetostat demonstrated an overall response rate (ORR) of 27% across cancer types, suggesting it could be best-in-class[13,16,18] - In 2L MTAP-del pancreatic cancer, the median progression-free survival (mPFS) was 7.2 months, with an ORR of 25%, supporting the planned pivotal study start in 2026[13,34] - The histology agnostic cohort (excluding sarcoma, pancreatic, and lung cancer) showed a 49% ORR and an mPFS of 9.1 months[13,51,53] Safety and Tolerability - Vopimetostat has a potential best-in-class safety and tolerability profile, with approximately 8% dose reduction and no drug-related dose discontinuations[13,25] Combination Studies and Future Plans - Ongoing combination study of vopimetostat + RAS(ON) inhibitors in 2L+ MTAP-del pancreatic and lung cancer patients, with expansion to first line (1L) cohort planned[13,43,45] - Lung cancer cohort is fully enrolled (n=41), with an update planned for 2026[13,48]

Financial Performance - Net income reached $188 million, with diluted earnings per share at $3.96, including a $38 million favorable discrete tax item and a $3 million post-tax impact from repurchased debt[5] - Adjusted net income was $191 million[7] - Revenue totaled $1 billion[7] - Tangible book value per common share increased by $8.88, or 19%, year-over-year to $56.36[5] - Return on average tangible common equity was 28.6%[5] Deposits and Funding - Direct-to-consumer deposits increased by 9% year-over-year to $8.2 billion, representing 47% of average total funding[5] Capital Allocation - The company announced a share repurchase authorization of $200 million in August and repurchased 0.6 million shares during the quarter[5] - An additional 0.4 million shares were repurchased in October, totaling 1 million shares for $60 million[5] - A $200 million increase to the share repurchase authorization was announced, bringing the total available to $340 million[5] - A quarterly cash dividend of $0.23 per common share was declared, a 10% increase from the prior quarter[5] Credit Quality - The delinquency rate decreased from 6.4% to 6.0% compared to the third quarter of 2024[12] - The net loss rate decreased from 7.8% to 7.4% compared to the third quarter of 2024[12]

Financial Performance - The company's total assets reached $7.9 billion[10] - Total gross loans amounted to $5.6 billion[10] - Total deposits were $6.4 billion[10] - The return on average assets was 1.50%[10] - The return on average equity was 14.88%[10] - Net income was $30.0 million[20] - Diluted earnings per share (EPS) were $1.97[20] Key Ratios and Metrics - The loan-to-deposit ratio was 86.7%[20, 38] - Uninsured deposits represented 31.5% of total deposits[20, 38] - The efficiency ratio was 56.3%[20] - The total risk-based capital ratio was 15.37%[20] - Tangible book value per common share was $48.72, with a growth of 15.8% from 4Q24 to 3Q25[20, 21]

Financial Performance - Q3 2025 Adjusted Funds From Operations (AFFO) increased by 8.7% to $36.1 million[10] - Q3 2025 AFFO per share increased by 5.1% to $0.62[10] - Year-to-date (YTD) AFFO increased by 7.3% to $103.9 million[14] - YTD AFFO per share increased by 3.4% to $1.80[14] Portfolio Metrics - The company invested $237 million at a 7.9% initial cash yield YTD[14] - The portfolio has a weighted average lease term (WALT) of 9.9 years[14] - The portfolio is 99.8% occupied[14] - Rent collections YTD stand at 99.9%[14] - Tenant rent coverage is 2.6x[14] Capital Structure and Liquidity - Net debt to EBITDA is 5.1x (4.6x pro forma for unsettled forward equity)[14] - The company has more than $375 million in total liquidity, including $5 million in cash, $113 million in unsettled forward equity, and $260 million in revolver capacity[14] - 84% of Annual Base Rent (ABR) is derived from unitary leases[20]

volatility of the Company's share price; risks related to currency fluctuations and foreign exchange controls; the potential impact of increased competition in the markets within which the Company operates, including competitive actions by other companies; the failure to respond to change and advancements in technology; risks relating to consolidation among commercial exhibitors and studios; risks related to brand extensions and new business initiatives; conditions in the in-home and out-of- home entertainm ...

Q3 2025 Earnings Presentation October 23, 2025 © 2025 TechnipFMC. All rights reserved. The information contained in this document is company confidential and proprietary property of TechnipFMC and its affiliates. It is to be used only for the benefit of TechnipFMC and may not be distributed, transmitted, reproduced, altered, or used for any purpose without the express written consent of TechnipFMC. Disclaimer Forward-looking statements This communication contains "forward-looking statements" as defined in S ...